Lenvatinib
- PDF / 169,898 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 57 Downloads / 161 Views
1
S
Thyroid-dysfunction and liver-dysfunction : 4 case reports In a retrospective study of 50 patients, conducted between April 2018 and November 2018, 4 patients [ages and sexes not stated] were described, who developed sub-clinical hypothyroidism, thyrotoxicosis or hepatic-coma leading to fatal hepatic-failure during treatment with levatinib for advanced hepatocellular carcinoma (HCC) [dosages not stated; not all outcomes stated]. The patients with advanced HCC started receiving oral levatinib. Thereafter, the patients developed sub-clinical hypothyroidism detected at week 8 post levatinib-initiation (1 patient), thyrotoxicosis detected at week 2 post levatinibinitiation and week 4 post levatinib-initiation, respectively (2 patients; one of the two patients was diagnosed with destructive thyroiditis that started 1 week post levatinib initiation) or grade 3 hepatic-coma on day 9 of levatinib therapy (1 patient). These events were related to levatinib therapy. The thyrotoxicosis episodes resolved. Therapy with levatinib was stopped in the patient, who developed hepatic-coma; on day 20 the patient died of hepatic-failure secondary to hepaticcoma. Author comment: "Hypothyroidism is also a frequent complication in patients treated with lenvatinib. However, studies on lenvatinib-induced thyroid toxicity and destructive thyroiditis are limited." "One patient with stage IVb HCC at the start of lenvatinib stopped treatment because of severe [adverse event] (hepatic coma) on day 9, and the patient died due to hepatic failure on day 20." Koizumi Y, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocrine Journal 66: 787-792, No. 9, 2019. Available 803435544 from: URL: http://doi.org/10.1507/endocrj.EJ19-0140 - Japan
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
